SAN DIEGO, Jan. 18 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer, today announced that Daniel P. Gold, Ph.D., Founder and Chief Scientific Officer, will present at the Brean Murray, Carret & Co. Small Cap Institutional Investor Conference at 1:30 p.m. EST on Wednesday, February 1, 2006. The conference will be held at the Grand Hyatt New York. Please note that attendance at the conference is by invitation only.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO )
Dr. Gold will provide an overview of the Company and the clinical trials of its lead compound, FavId, for the treatment of B-cell non-Hodgkin’s lymphoma (NHL). A live webcast of the presentation can be accessed at www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until March 1, 2006.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company’s lead product candidate, FavId, is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.
CONTACT: Pete De Spain, Associate Director, Investor Relations & CorporateCommunications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com/
